middle.news
Dimerix Opens Post-Trial Access to DMX-200 for FSGS Patients
8:46am on Thursday 9th of July, 2026 AEST
•
Biotechnology
Read Story
Dimerix Opens Post-Trial Access to DMX-200 for FSGS Patients
8:46am on Thursday 9th of July, 2026 AEST
Key Points
Post-trial access enables ongoing DMX-200 treatment for eligible FSGS patients
Access pathways vary by jurisdiction, including expanded and compassionate use
Commercial partners manage access in licensed territories; Dimerix covers unlicensed regions
DMX-200 remains investigational; data collection during post-trial access limited to safety
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE